Aug. 18 at 6:36 AM
$AMIX caught our attention because a few things are lining up at the same time. The company reported roughly
$5.1 million in cash with fewer than 1 million shares outstanding, giving it an unusually tight share structure. It has also been steadily moving its technology forward, most recently completing a GLP preclinical study that supports its path toward an FDA submission. We’ve already seen what can happen when interest comes into the name: AMIX went from
$3.65 to
$19.50 in a single session on August 4, trading more than 115 million shares. With a small float, improving regulatory momentum and a steady flow of patents and development updates, AMIX has the ingredients for another sharp move if buying interest picks up again.
